Then they go back into your body. The CAR T cells target an antigen called CD19 on your lymphoma cells. The FDA has approved several CAR T-cell therapies for certain people with follicular lymphoma.

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

CAR T-cell therapy uses your own immune cells to fight cancer in a new way. It changes immune cells called T cells so they target tumors directly. It’s been approved to treat certain types of ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase ... A rapidly developed, dual-target chimeric antigen receptor T-cell ...

In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy ...

Jenna had been diagnosed with lymphoma in 2020 and, after relapsing post-chemotherapy, she hoped a personalized treatment option called CAR T cell therapy ... specific target cells, which may ...

If approved, ZAMTO Cell would be the first dual-target CAR-T therapy ... institutions are now working on CAR-T therapies targeting not just B-cell lymphoma but also multiple myeloma and solid ...

In this case, HSP-CAR30 is designed to target the CD30 protein, which is present in tumor cells in Hodgkin lymphoma and other CD30+ lymphomas, and rarely expressed in healthy cells. The challenge with ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...